CT.gov Condition Hiddenness Map
2026-03-29 | full-registry ct.gov audit | plots, figures, and e156 bundle
Series
IndustrySponsor ClassesPhasesStructuralVisibilityCohortsConditionsConcentration
Condition Dashboard

Therapeutic-area hiddenness looks different once the registry is mapped into condition families

Oncology contains the biggest eligible stock, while healthy-volunteer studies are the quietest common family on the ghost-protocol metric.

Open dashboardRead E156 paperProtocolSeries hub
Stock by family
Ghost rate
Visible share
Keyword families

Dashboard

Open dashboard at rootRead E156 micro-paperOpen protocolOpen series hub

Family mapping turns a shapeless registry into an interpretable therapeutic-area landscape, even with a simple keyword classifier.

How to read the dashboard
Named families
13
Excluding Other
Oncology stock
42,344
Largest named family
Healthy-volunteer ghosts
63.5%
Quietest common family
Infectious visible
20.6%
Best common-family visibility
Stock by family
FAMILY STOCKEligible older study counts by named condition familyOncology42,344Cardiovascular26,062Mental health18,501Infectious disease18,016Musculoskeletal and pain17,443Metabolic17,294Healthy volunteers14,119Neurology10,127Respiratory and sleep9,062Gastrointestinal and hepatic6,898
Oncology is the largest named family by stock, followed by cardiovascular and mental-health groups.
Stock identifies where the broadest therapeutic blocks of potentially missing evidence sit inside the registry.
Ghost rates by family
FAMILY GHOST RATESGhost-protocol rate among common condition familiesHealthy volunteers63.5%Gastrointestinal and hepatic45.1%Musculoskeletal and pain44.0%Reproductive and maternal42.6%Oncology42.5%Metabolic41.9%Renal and urology41.4%Neurology40.5%Respiratory and sleep39.9%Immunology and dermatology39.9%
Healthy volunteers and gastrointestinal-hepatic families sit high on the ghost-protocol axis.
Ghost rate shows where older studies are most likely to have neither results nor a linked publication path.
Fully visible share
FAMILY VISIBILITYShare of older studies with both results and publication by familyInfectious disease20.6%Immunology and dermatology18.9%Respiratory and sleep16.5%Neurology15.3%Renal and urology15.3%Oncology15.0%Mental health14.9%Metabolic14.1%Cardiovascular13.8%Gastrointestinal and hepatic12.2%
Infectious-disease and respiratory-sleep trials sit toward the top on full visibility, even though neither family is clean.
The positive view matters because a family can look bad on stock without being the worst on complete evidence visibility.
Read Across Projects

Across The Series

Each project isolates a different dimension of registry opacity, but the point is the contrast between them, not a single leaderboard.

Industry
CT.gov Industry Disclosure Gap

Industry-focused missing-results stock, sponsor backlogs, and structural sparsity inside CT.gov.

Sponsor Classes
CT.gov Sponsor-Class Hiddenness

Sponsor-class comparisons on rate, stock, and structural hiddenness rather than one flattened ranking.

Phases
CT.gov Phase Reporting Gap

Phase-by-phase disclosure gaps showing how silence changes along the development pathway.

Structural
CT.gov Structural Missingness

Field-level missingness across publication links, IPD statements, descriptions, and locations.

Visibility
CT.gov Evidence Visibility Gap

Results-plus-publication visibility states showing how many older trials are fully visible, partly visible, or ghosted.

Cohorts
CT.gov Completion Cohort Debt

Completion-era reporting debt showing how older eligible cohorts drift on no-results and ghost-protocol rates.

Concentration
CT.gov Sponsor Backlog Concentration

Concentration and inequality analysis showing how much unresolved stock sits inside a thin sponsor slice.

Source on GitHub | Project home | Dashboard